The role of levetiracetam in treatment of seizures in brain tumor patients

Frontiers in Neurology

Volumn 4 OCT, Issue , 2013, Pages

  Fonkem, Ekokobe ^a,b   Bricker, Paul ^b   Mungall, Diana ^b   Aceves, Jose ^b,c   Ebwe, Eromata ^a   Tang, Wei ^a,b   Kirmani, Batool ^b,c  

^a Scott and White Healthcare   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Brain tumor patients; Intravenous levetiracetam; Neurologic complications; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CORTICOSTEROID; CYTOCHROME P450; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; MEMBRANE PROTEIN; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; SYNAPTIC VESICLE PROTEIN; TEMOZOLOMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; ZONISAMIDE;

ALLERGY; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CALCIUM TRANSPORT; CANCER PREVENTION; CANCER RADIOTHERAPY; CAUSE OF DEATH; CELL DEATH; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPENDYMOMA; EPILEPTIC STATE; GLIOBLASTOMA; GLIOMA; HISTONE ACETYLATION; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; LIVER DYSFUNCTION; LUNG DISEASE; MENINGIOMA; MONOTHERAPY; MORBIDITY; NAUSEA; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROSURGERY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEOMORPHIC XANTHOASTROCYTOMA; POSTOPERATIVE PERIOD; RASH; REFRACTORY PERIOD; REVIEW; SEIZURE; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84885338717     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00153     Document Type: Review

References (42)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia (1993) 34:453-68. doi: 10.1111/j.1528-1157.1993.tb02586.x.
2. Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology (2002) 59(Suppl 5):S21-6. doi:10.1212/WNL.59.9_suppl_5.S21.
3. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 54:1886-93. doi:10.1212/WNL.54.10.1886.
4. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol (2003) 30:45-8. doi:10.1053/j.seminoncol.2003.11.023.
5. van Breemen RM, Rijsman RM, Taphoorn MJB, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol (2009) 256:1519-26. doi:10.1007/s00415-009-5156-9.
6. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol (1995) 52:717-24. doi:10.1001/archneur.1995.00540310091021.
7. Tsai H, Wei K, Tsai C, Huang Y, Chen P, Chen S, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg (2012) 26(3):347-54. doi:10.3109/02688697.2011.638996.
8. Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, et al. Levetiracetam therapy in patients with brain tumor and epilepsy. J Neurooncol (2006) 80:97-100. doi:10.1007/s11060-006-9162-9.
9. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol (2002) 24:130-3. doi:10.1097/00043426-200202000-00014.
10. Grossman F. A review of anticonvulsants in treating agitated demented elderly patients. Pharmacotherapy (1998) 18:600-6.
11. Maschio M, Dinapoli L. Lecture: profile of risks and benefits of new antiepileptic drugs in brain tumor-related epilepsy. Neurol Sci (2011) 32(Suppl 2):S259-62. doi:10.1007/s10072-011-0801-3.
12. Van Breemen MS, Vecht CJ. Optimal seizure management in brain tumor patients. Curr Neurol Neurosci Rep (2005) 5:207-13. doi:10.1007/s11910-005-0048-6.
13. Baulac M, Brodie MJ, Elger CE, Krakow K, Stockis A, Meyvisch P, et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia (2007) 48:589-92. doi:10.1111/j.1528-1167.2006.00959.x.
14. Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidri A, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability, and impact on quality of life. J Neurooncol (2012) 106:651-6. doi:10.1007/s11060-011-0689-z.
15. Meyer FP, Banditt P, Schubert A, Schoche J. Lamotrigine concentrations in human serum, brain tissue, and tumor tissue. Epilepsia (1999) 40:68-73. doi:10.1111/j.1528-1157.1999.tb01990.x.
16. Swisher C, Doreswamy M, Gingrich K, Vredenburgh J, Kolls B. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit Care (2012) 16:109-13. doi:10.1007/s12028-011-9626-4.
17. Saria M, Corle C, Hu J, Rudnick J, Phuphanich S, Mrugala M, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg (2013) 118:1183-7. doi:10.3171/2013.1.JNS12397.
18. Maschio M, Dinapoli L, Mingoia M, Sperati F, Pace A, Pompili A, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol (2011) 258:2100-4. doi:10.1007/s00415-011-6132-8.
19. Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia (2009) 50:387-97. doi:10.1111/j.1528-1167.2008.01713.x.
20. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A (2004) 101:9861-6. doi:10.1073/pnas.0308208101.
21. Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia (2007) 48:1861-9. doi:10.1111/j.1528-1167.2006.01132.x.
22. Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs (2011) 71:489-514.
23. Ruggiero A, Rizzo D, Mastrangelo S, Battaglia D, Attina G, Riccardi R. Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? Pediatr Blood Cancer (2010) 54(2):193-8. doi:10.1002/pbc.22276.
24. Wagner GL, Wilms EB, Van Donselaar CA, Vecht CHJ. Levetiracetam: preliminary experience in patients with primary brain tumors. Seizure (2003) 12:585-6. doi:10.1016/S1059-1311(03)00096-7.
25. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol (2006) 78:99-102. doi:10.1007/s11060-005-9070-4.
26. Siddiqui F, Wen P, Dworetzky B, Cabello D, Bromfield EB. Use of levetiracetam in patients with brain tumors. Epilepsia (2002) 43(Suppl 7):297.
27. Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol (2010) 67:343-6. doi:10.1001/archneurol.2009.335.
28. Dinappoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci (2009) 30:353-9. doi:10.1007/s10072-009-0087-x.
29. Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res (1998) 17:479-82.
30. Liigant A, Haldre S, Oun A, Linnamagi U, Saar A, Asser T, et al. Seizure disorders in patients with brain tumors. Eur Neurol (2001) 45:46-51. doi:10.1159/000052089.
31. Stevens GHJ, Vogelbaum MA, Suh JH, Peereboom DM, Barnett GH. Levetiracetam use in brain tumor patients. Neurology (2005) 64:A48.
32. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Levetiracetam monotherapy in patients with brain tumor related epilepsy: seizure control, safety and quality of life. J Neurooncol (2011) 104:205-14. doi:10.1007/s11060-010-0460-x.
33. Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology (2005) 65:212-5. doi:10.1212/01.wnl.0000168903.09277.8f.
34. DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, et al. A prospective population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology (1996) 46:1029-35. doi:10.1212/WNL.46.4.1029.
35. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci (2003) 211:37-41. doi:10.1016/S0022-510X(03)00036-4.
36. Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir (Wien) (2012) 154:229-35. doi:10.1007/s00701-011-1144-9.
37. Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neurooncol (2011) 101:101-6. doi:10.1007/s11060-010-0235-4.
38. Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology (2008) 71:665-9. doi:10.1212/01.wnl.0000324624.52935.46.
39. Strahl BD, Allis CD. The language of covalent histone modifications. Nature (2000) 403:41-5. doi:10.1038/47412.
40. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p-53 mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol (2010) 12:917-27. doi:10.1093/neuonc/noq044.
41. Ueda Y, Doi T, Takaki M, Nagatomo K, Nakajima A, Willmore LJ. Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy. Brain Res (2009) 1266:1-7. doi:10.1016/j.brainres.2009.02.040.
42. Cardile V, Pavone A, Gulino R, Renis M, Scifo C, Perciavalle V. Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase in rat astrocyte cultures treated with levetiracetam. Brain Res (2003) 976:227-33. doi:10.1016/S0006-8993(03)02720-3.